Comparison of Teneligliptin and Luseogliflozin on Pancreatic β-cell Function

Study Overview

This study aims to compare the effects of two medications, SGLT2 inhibitors (luseogliflozin) and DPP-4 inhibitors (teneligliptin), on pancreatic β-cell function in patients with type 2 diabetes.

Study Details

We conducted a 26-week study with 103 patients who had type 2 diabetes. Participants were randomly assigned to take either luseogliflozin or teneligliptin. The main goal was to measure changes in β-cell function using an oral glucose tolerance test.

Key Findings

Improvement in β-cell Function: Both medications showed improvements in β-cell function, but luseogliflozin had a more significant effect on reducing β-cell dysfunction compared to teneligliptin.
Results:
- Luseogliflozin group: Improved from -0.46 to -0.20 (p=0.03)
- Teneligliptin group: Improved from -0.26 to -0.05 (p=0.01)
Proinsulin/C-peptide Ratio: This ratio decreased in the luseogliflozin group but increased in the teneligliptin group, indicating better β-cell function with luseogliflozin.

Conclusion

Both medications improved β-cell function in patients with type 2 diabetes, but luseogliflozin was more effective at reducing β-cell dysfunction.

Clinical Trial Registration

For more information, visit: Clinical Trial Registration

Value of Clinical Trials

Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, helps integrate clinical standards and research into a user-friendly resource for healthcare providers.

Enhancing Patient Care

In today’s healthcare landscape, efficiency is vital. Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, simplifying patient management and expanding digital services.